Abstract: A method for detecting organic matter in the blood by using LDI-MS, and a device therefor, according to the present invention, are not complicated when performing measurement and do not require the passage of many steps, and facilitate, in real time, measurement and result collection through rapid analysis. In addition, the present invention enables precise analysis even at a lower sample concentration so as to have excellent sensitivity and accuracy, enables the detection of various types of organic matter at the same time and has high throughput, and enables the structure analysis of organic matter, having undergone metabolic processes in the blood, and quantitative analysis thereof to be accurately performed without interference from a matrix.

Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.

Abstract: A reverse osmosis filtering module includes: a purified water discharge pipe in which a purified water discharge path is formed, and which has a communication hole that is formed on an outer periphery thereof and communicates with the purified water discharge path; a reverse osmosis filtering part including a reverse osmosis filtering member in which a purified water flow space is formed, and which is wound around the purified water discharge pipe such that the purified water flow space communicates with the communication hole; a first flow channel formation cap provided at one side and having an inlet hole; and a second flow channel formation cap provided at the other side of the reverse osmosis filtering part and having an outlet hole.

Abstract: Image panning method is disclosed. Embodiments provide a method performed by a device for placing a second object on a first object on screen, including moving the first object on screen, responsive to a drag moving the second object over the first object in a first direction, in a second direction opposite to the first direction, and placing the second object at end position of the drag in the first object, when the drag is terminated for the second object. The method allows a drag for moving the second object to a vicinity of an end of the first object or to an outside area of the first object beyond the end of the first object.

Abstract: The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor or expression inhibitor as an active ingredient.

Abstract: A method for controlling autonomous driving in an autonomous vehicle includes detecting an autonomous driving-related critical situation during the autonomous driving, outputting a notification message requesting a control-right handover from an autonomous driving system to a human driver when the autonomous driving-related critical situation is detected, and activating a minimal risk maneuver (MRM) driving mode to deactivate the autonomous driving system when the control-right handover is not successful. In particular, when the minimal risk maneuver (MRM) driving mode is activated, the deactivated state of the autonomous driving system is maintained until an engine-restart of the autonomous vehicle is detected.

Abstract: A system for obtaining state information of a battery may be disclosed. The system includes: at least one first harness cable for obtaining, on the basis of a CAN protocol, data indicating state information of the battery from a battery management system of the battery; an analyzer for providing a driving signal for driving the battery management system; and a first junction box for transmitting the data input through the first harness cable to the analyzer, wherein the analyzer may be configured to output the data received from the first junction box to the outside.

Abstract: The present invention relates to a method for high-sensitivity and high-specificity detection of biomolecules by using mass spectrometry and, more specifically, to a method for high-sensitivity and high-specificity detection of proteins such as miRNA or antigens by using time-of-flight secondary ion mass spectrometry (ToF-SIMS), matrix-assisted laser desorption/ionization (MALDI), or laser desorption/ionization (LDI) mass spectrometry. The method for high-sensitivity and high-specificity detection of biomolecules by using mass spectrometry, according to the present invention, enables high-sensitivity and high-specificity detection of biomolecules by using surface mass spectrometry, and the method is expected to be used for the diagnosis and prediction of diseases by quantifying, from a biosample, a target probe such as miRNA which is known as a disease marker.

Abstract: An autonomous driving control apparatus for a vehicle includes: a processor that determines whether a current driving condition of the vehicle is a limit situation during an autonomous driving control, performs a demand for control authority transition to a user during the autonomous driving control when the current driving condition is the limit situation, and starts a minimum risk maneuver to transmit a signal for disabling reactivation of the autonomous driving control when control authority is not transferred to the user; and a storage to store a set of instructions and driving condition data to be used by the processor. In particular, the processor demands for engagement of an electronic parking brake device when the vehicle is stopped after the minimum risk maneuver ends.

Abstract: An autonomous driving control apparatus for a vehicle includes: a processor that demands a user of a vehicle to take a control authority of the vehicle during an autonomous driving control when a current driving condition is in a limit situation during the autonomous driving control, and starts a minimum risk maneuver to disable reactivation of the autonomous driving control when the control authority is not transferred to the user; and a storage to store a set of instructions to be executed by the processor and data for determination and performance by the processor. In particular, the processor automatically flashes an emergency light when the minimum risk maneuver is started, and controls automatic flashing of the emergency light to not be released by the user when the vehicle is not in a stopped state.

Abstract: Disclosed herein is a method of connection of home appliance to a network, a network-connection system for home appliances, and an apparatus related to a network-connection setting for home appliances. The network connection method of home appliance includes operations in which a terminal device receives an input of an authentication key of an access point (AP) apparatus and the terminal device or the AP apparatus verifies and authenticates the authentication key; a home appliance is set to be in a state of communicating with the terminal device; the home appliance is interconnected to the terminal device and the terminal device transmits an identification number and the certificated authentication key of the AP apparatus to the home appliance; and the home appliance is connected to the AP apparatus based on the identification number and the authentication key of the AP apparatus.

Abstract: The present invention relates to a composition for diagnosing diseases associated with cyclooxygenase 2 (COX2) overexpression and a screening method therefor and, more particularly, to: a composition for diagnosing diseases associated with COX2 overexpression, containing a compound with a structural feature of exhibiting strong binding activity to a COX2 protein; and a screening method therefor.

Abstract: Disclosed herein is a method of connection of home appliance to a network, a network-connection system for home appliances, and an apparatus related to a network-connection setting for home appliances. The network connection method of home appliance includes operations in which a terminal device receives an input of an authentication key of an access point (AP) apparatus and the terminal device or the AP apparatus verifies and authenticates the authentication key; a home appliance is set to be in a state of communicating with the terminal device; the home appliance is interconnected to the terminal device and the terminal device transmits an identification number and the certificated authentication key of the AP apparatus to the home appliance; and the home appliance is connected to the AP apparatus based on the identification number and the authentication key of the AP apparatus.

Abstract: A communication method of an electronic device may comprise: a step of wirelessly outputting an advertisement signal at predetermined time intervals when power is supplied; a step of acquiring access information of an access repeater from an external device while outputting the advertisement signal; a step of stopping the output of the advertisement signal and accessing the access repeater on the basis of the access information of the access repeater when the access information of the access repeater is acquired; and a step of stopping the output of the advertisement signal if an elapsed time after the power is supplied is greater than a predetermined reference time.

Abstract: An organic light-emitting diode display device includes a first substrate that includes a display region with a plurality of pixels and a non-display region in a periphery of the display region, a first electrode disposed on the first substrate, a second electrode opposed to the first electrode, an organic light-emitting layer disposed between the first electrode and the second electrode, and at least one light sensing member disposed on a rear surface of the first substrate that overlaps the display region.

Abstract: The present invention relates to a composition for preventing or treating neurodegenerative diseases or depression, containing a 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative as an active ingredient and more specifically, to a pharmaceutical composition for preventing or treating neurodegenerative diseases or depression, containing, as an active ingredient, the compound having an effect of directly inhibiting ASM activity.

Abstract: A skin-penetrating carrier containing a nucleic acid complex having a novel structure which introduces a bioactive nucleic acid into cells. Composition for diagnosing, preventing or treating disease and to a skin-penetrating carrier containing a nucleic acid complex in which a bioactive nucleic acid and a carrier peptide nucleic acid are complementarily bound to each other, and having skin permeability and skin retention ability. Skin-penetrating carrier containing nucleic acid complex having structure of Structural Formula (1) has both a skin penetration function of effectively delivering a large-molecular-weight drug and in vivo effectiveness. Carrier enables bioactive nucleic acids or various compounds to pass through the epidermis and dermis of the skin, thus enables external treatment by application to the skin surface.

Abstract: The present invention relates to a nucleic acid complex having a novel structure, which may introduce a bioactive nucleic acid into cells, a composition for treating or diagnosing disease comprising the same, and a method of regulating target gene expression using the same, and more particularly to a nucleic acid complex in which a bioactive nucleic acid, which comprises a material for facilitating endosomal escape, and a carrier peptide nucleic acid, are complementarily bound to each other, a composition for treating or diagnosing disease comprising the same, a composition for regulating target gene expression using the same, and a method of regulating target gene expression using the same.

Abstract: The present invention relates to a pharmaceutical composition containing stem cells in which vascular endothelial growth factor (VEGF) is overexpressed as an effective ingredient for preventing or treating neurodegenerative diseases. The stem cells in which VEGF is overexpressed according to the present invention effectively act against the neurodegenerative disease-induced VEGF reduction of neural stem cells in the SVC to inhibit the abnormal migration of neural stem cells, suppress inflammatory responses, and restrain the accumulation of cholesterol and spingolipids in the cerebral cortex, thus restoring the behavior exercise capacity of animal models, whereby the pharmaceutical composition can be used as an effective therapeutic agent for neurodegenerative diseases.

Abstract: The present invention relates to a novel use for HDL-ApoM-S1P (a high density lipoprotein in which apolipoprotein M is impregnated with sphingosine-1-phosphate), and more particularly, to using HDL-ApoM-S1P to prevent, improve, or treat degenerative brain disorders (in particular, Alzheimer's disease), cognitive disorders, learning disabilities, and memory disorders, and using HDL-ApoM-S1P to improve cognitive ability, learning ability, and memory. The HDL-ApoM-S1P according to the present invention not only alleviates neuroinflammation but also significantly exhibits improvement effects of cognitive disorder, learning disability, and memory disorder with respect to individuals suffering from degenerative brain disorders (in particular, Alzheimer's disease), and exhibits an effect of greatly reducing amyloid beta and tau deposition. Moreover, increased HDL-ApoM-S1P in the body also has an excellent effect of improving the cognitive, learning, and memory abilities of non-disabled individuals.